<![CDATA[Zanubrutinib/Rituximab Improves PFS in Frontline Mantle Cell Lymphoma]]>

Phase 3positiveZanubrutinib/RituximabPositive

AI Analysis

Summary

Phase 3 MANGROVE trial data shows Zanubrutinib/Rituximab improves PFS in frontline mantle cell lymphoma, with full results to be presented at an upcoming medical meeting and global regulatory submissions planned for H2 2026.

Clinical Trial Data

Phase

Primary Endpoint

Met

Outcome Details

Zanubrutinib/Rituximab improves PFS in frontline mantle cell lymphoma

Importance:7/10

Sentiment:

0.70

Phase 3Mantle Cell LymphomaMANGROVE trialPFS improvementRegulatory submission planned

Related Companies

$BGNE

Read the original article

Published by Cancer Network on July 1, 2026 2:30 PM

Read Original